Xiang Yufei, Huang Gan, Shan Zhongyan, Pan Linlin, Luo Shuoming, Yang Liyong, Shi Lixin, Li Qifu, Leslie R David, Zhou Zhiguang
Institute of Metabolism and Endocrinology, The Second Xiangya Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, National Clinical Research Center for Metabolic Diseases, Changsha, 410011, China.
Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, Shenyang, China.
Acta Diabetol. 2015 Dec;52(6):1121-7. doi: 10.1007/s00592-015-0799-8. Epub 2015 Aug 5.
AIMS: Adult-onset autoimmune diabetes is prevalent in China, in contrast to childhood-onset type 1 diabetes mellitus. Islet autoantibodies are the most important immune biomarkers to diagnose autoimmune diabetes. We assayed four different islet autoantibodies in recently diagnosed adult non-insulin-requiring diabetes Chinese subjects to investigate the best antibody assay strategy for the correct diagnosis of these subjects. METHODS: LADA China study is a nation-wide multicenter study conducted in diabetes patients from 46 university-affiliated hospitals in China. Non-insulin-treated newly diagnosed adult diabetes patients (n = 2388) were centrally assayed for glutamic acid decarboxylase autoantibody (GADA), protein tyrosine phosphatase-2 autoantibody (IA-2A), and zinc transporter 8 autoantibody (ZnT8A) by radioligand assay and insulin autoantibody (IAA) by microtiter plate radioimmunoassay. Clinical data were determined locally. RESULTS: Two hundred and six (8.63 %) subjects were autoantibody positive, of which GADA identified 5.78 % (138/2388) of the total, but only 67 % (138/206) of the autoimmune cases. IA-2A, ZnT8A, and IAA were found in 1.51, 1.84, and 1.26 % of the total study subjects, respectively. When assaying three islet autoantibodies, the most effective strategy was the combination of GADA, ZnT8A, and IAA, which could identify 92.2 % (190/206) autoimmune diabetes patients. The clinical data showed that those subjects with positive GADA had lower random C-peptide than autoantibody negative subjects (P < 0.05). CONCLUSIONS: As with Europeans, GADA is the dominant autoantibody in this form of autoimmune diabetes in China, but in contrast to Europeans, screening should include other diabetes-associated autoantibodies.
目的:与儿童期发病的1型糖尿病不同,成人发病的自身免疫性糖尿病在中国较为普遍。胰岛自身抗体是诊断自身免疫性糖尿病最重要的免疫生物标志物。我们检测了近期诊断的非胰岛素依赖型成年中国糖尿病患者的四种不同胰岛自身抗体,以研究正确诊断这些患者的最佳抗体检测策略。 方法:LADA中国研究是一项在中国46家大学附属医院的糖尿病患者中开展的全国性多中心研究。对2388例未经胰岛素治疗的新诊断成年糖尿病患者集中检测谷氨酸脱羧酶自身抗体(GADA)、蛋白酪氨酸磷酸酶2自身抗体(IA-2A)和锌转运体8自身抗体(ZnT8A),采用放射性配体分析法,胰岛素自身抗体(IAA)采用微量滴定板放射免疫分析法。临床数据在当地测定。 结果:206例(8.63%)受试者自身抗体呈阳性,其中GADA在全部受试者中占5.78%(138/2388),但仅占自身免疫病例的67%(138/206)。IA-2A、ZnT8A和IAA分别在全部研究受试者中占1.51%、1.84%和1.26%。检测三种胰岛自身抗体时,最有效的策略是联合检测GADA、ZnT8A和IAA,可识别92.2%(190/206)的自身免疫性糖尿病患者。临床数据显示,GADA阳性的受试者随机C肽水平低于自身抗体阴性的受试者(P<0.05)。 结论:与欧洲人一样,GADA是中国这种自身免疫性糖尿病形式中的主要自身抗体,但与欧洲人不同的是,筛查应包括其他糖尿病相关自身抗体。
Diabetes Metab Res Rev. 2010-10
Curr Diabetes Rev. 2019
Diabetes Technol Ther. 2022-3
Nat Rev Endocrinol. 2025-2
Diabetes Care. 2024-5-1
Front Immunol. 2022
Front Endocrinol (Lausanne). 2022
Diabetes Metab Res Rev. 2010-10